[1] Bouhnik Y, Carbonnel F, Laharie D, et al. Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicenter,prospective,observational cohort (CREOLE)study[J].Gut, 2018,67(1):53-60. DOI:10.1136/gutjnl-2016-312581.
[2] 李玉林.病理学[M].9版.北京:人民卫生出版社,2019:215-216.
[3] Banfi D, Moro E, Bosi A, et al. Impact of microbial metabolites on microbiota-gut-brain axis in inflammatory bowel disease [J]. Int J Mol Sci, 2021, 22(4): 1623. DOI: 10.3390/ijms22041623.
[4] 范晓萱,赵斌,张青青等.肠道菌群在失眠症发病机制中的研究进展[J].中国临床新医学,2021,14(12):1246-1249. DOI:10.3969 /j.issn.1674-3806.2021.12.20.
[5] Bhandage AK, Barragan A. GABAergic signaling by cells of the immune system: more the rule than the exception [J]. Cell Mol Life Sci, 2021, 78(15): 5667-5679. DOI: 10.1007/s00018-021-03881-z.
[6] Paul AM, Branton WG, Walsh JG, et al. GABA transport and neuroinflammation are coupled in multiple sclerosis: regulation of the GABA transporter-2 by ganaxolone [J]. Neuroscience, 2014, 273: 24-38. DOI: 10.1016/j.neuroscience.2014.04.037.
[7] 中华医学会消化病学分会炎症性肠病学组.炎症性肠病诊断与治疗的共识意见(2018年•北京)[J]. 中国实用内科杂志,2018,38(9):796-813. DOI:10.19538/j.nk2018090106.
[8] 张镕宇,李伊敏,陈桂权等.硒结合蛋白1在克罗恩病组织中的表达水平及其与患者炎性状态和预后的关系[J].国际消化病杂志,2020,10(40):303-308. DOI:10.3969/j.issn.1673-534X.2020.05.005.
[9] 张月凡,张维婕,胡家骏,等. MUC5AC和CDX-2在胃癌组织中的表达及其与临床病理特征及预后的相关性[J]. 临床和实验医学杂志,2020,19(21):2282-2285. DOI:10.3969/j.issn.1671-4695.2020.21.012.
[10] 葛文松.提高克罗恩病早诊早治水平改善疗效和预后[J/CD].中国现代医学杂志(电子版),2021,11(1):28-30. DOI:10.3877/cma.j.issn.2095-2015.2021.01.006.
[11] 冉志华.炎症性肠病诊断与治疗的共识意见(2012年•广州)克罗恩病诊断的部分解读[J]. 胃肠病学.2012,17(12):721-723. DOI: 10.3969/j.issn.1008-7125.2012.12.004.
[12] 中华医学会消化病学分会炎症性肠病学组病理分组.中国炎症性肠病病理诊断专家指导意见[J].中华炎性肠病杂志,2021,1(5):1-16. DOI:10.3760/cma.j.cn101480- 20200731- 00086.
[13] Pellegrini C, Antonioli L, Calderone V, et al. Microbiota-gut-brain axis in health and disease: is NLRP3 inflammasome at the crossroads of microbiota-gut-brain communications?[J]. Prog Neurobiol,2020, 191:101806. DOI:10.1016/j.pneurobio.2020.101806.
[14] Bistoletti M, Bosi A, Banfi D, et al. The microbiota-gut-brain axis: Focus on the fundamental communication pathways [J]. Prog Mol Biol Transl Sci, 2020, 176: 43-110. DOI: 10.1016/bs.pmbts.2020.08.012.
[15] Baj A, Moro E, Bistoletti M, et al. Glutamatergic signaling along the microbiota-gut-brain axis[J]. Int J Mol Sci, 2019, 20(6):1482. DOI:10.3390/ijms20061482.
[16] Strandwitz P, Kim KH, Terekhova D, et al. GABA-modulating bacteria of the human gut microbiota [J]. Nat Microbiol, 2019, 4(3):396-403. DOI: 10.1038/s41564-018-0307-3.
[17] Wu C, Qin X, Du H, et al. The immunological function of GABAergic system[J].Front Biosci (Landmark Ed), 2017, 22(7): 1162-1172. DOI:10.2741/4539.
[18] Ren W, Liao Y, Ding X, et al. Slc6a13 deficiency promotes Th17 responses during intestinal bacterial infection [J]. Mucosal Immunol, 2019, 12(2): 531-544. DOI: 10.1038/s41385-018-0111-7.
[19] Xia Y, He F, Wu X, et al. GABA transporter sustains IL-1β production in macrophages [J]. Sci Adv, 2021, 7(15): eabe9274. DOI: 10.1126/sciadv.abe9274.
[20] Ding X, Bin P, Wu W, et al. Tryptophan metabolism, regulatory T cells, and inflammatory bowel disease: a mini review [J]. Mediators Inflamm, 2020:9706140. DOI: 10.1155/2020/9706140.
|